Table 1.
Baseline characteristics of PACE participants (2008–2012)
| Variables | N | Mean (± SD), median (IQR), or frequency (%) |
|---|---|---|
| Demographics | ||
| Total number | 391 | |
| Age, years | 55.0 ± 13.2 | |
| Sex | ||
| Male | 234 (60) | |
| Female | 157 (40) | |
| Race | ||
| African American | 283 (72) | |
| Non–African American | 108 (28) | |
| Cardiovascular disease risk factors | ||
| Body mass index, kg/m2 | 386 | 29.6 ± 7.8 |
| Hypercholesterolemia | 391 | 269 (69) |
| Ever smoker | 390 | 236 (61) |
| Diabetes mellitus | 391 | 225 (58) |
| Coronary artery disease | 391 | 143 (37) |
| Congestive heart failure | 391 | 161 (41) |
| Charlson comorbidity index | 391 | 5 (4–6) |
| Systolic blood pressure, mm Hg | 388 | 137.6 ± 25.5 |
| Diastolic blood pressure, mm Hg | 388 | 74.7 ± 14.7 |
| Dialysis laboratory measurementsa | ||
| Serum phosphate, mg/dl | 388 | 4.97 ± 1.04 |
| Corrected serum calcium, mg/dl | 388 | 8.94 ± 0.49 |
| Calcium-phosphate product, mg2/dl2 | 388 | 42.4 ± 8.76 |
| Serum albumin, g/dl | 388 | 3.54 ± 0.48 |
| PTH, pg/ml | 389 | 420 (272–611) |
| Biochemical measurements | ||
| dp-ucMGP, ppm | 364 | 1412 (957–2070) |
| Osteoprotegerin, pmol/l | 383 | 10.9 ± 4.9 |
| Fetuin-A, g/l | 383 | 0.51 ± 0.17 |
| FGF23, RU/ml | 382 | 527 (241–1125) |
| Klotho, pg/ml | 367 | 365 (273–500) |
| C-reactive protein, μg/ml | 383 | 5.86 (2.30–15.1) |
| Baseline dietary intake | ||
| Vitamin K, μg | 305 | 44.4 (24.3–98.5) |
| Phosphate, mg | 326 | 779.8 (546.0–1108.0) |
dp-ucMGP, dephosphorylated-uncarboxylated matrix Gla protein; FGF23, fibroblast growth factor 23; IQR, interquartile range; PTH, parathyroid hormone; SD, standard deviation.
a
Corresponds to 3-month average from start of dialysis.